A study published in September 2017, titled: ‘Quality of life after brachytherapy or bilateral nerve‐sparing robot‐assisted radical prostatectomy for prostate cancer: a prospective cohort’, compared patient quality of life after either brachytherapy or radical prostatectomy treatments.
New guidelines around PSA testing promise to transform prostate cancer outcomes in Australia. The guidelines, which recommend that asymptomatic men between the ages of 50-69 are offered PSA testing every two years1, replace US Preventative Services Task Force guidelines and previous differing guidelines in Australia that some urologists blame for an increase in presentations with metastatic prostate cancer2. Certainly, when screening was discouraged, adverse consequences followed, with evidence showing that mortality from prostate cancer is lower when men are screened for it3. With prostate ca...
Claire Deering, Brachytherapy Clinical Nurse Specialist at Royal Surrey County Hospital NHS Foundation Trust, explains why it’s important for prostate nurse specialists to build and share their knowledge of brachytherapy – even in centres where it isn’t currently offered.
Prostate cancer is the most common form of cancer in men, and will directly or indirectly effect most of us in our lifetime. With new research showing that half of prostate cancer patients undergo treatment without knowing their treatment options, it is more important than ever to talk openly about this disease and the full range of choices available when deciding upon treatment.
Due to its intimate nature, it is understandable that you may feel uncomfortable when it comes to discussing your symptoms or treatment options for prostate cancer. But with the wide range of options now available, and the varying outcomes and side effects these treatments might present for patients with different lifestyle choices, it is now more important than ever that you should feel confident in discussing your condition and empowered to seek specialist advice on all the possible treatment options available – some of which offer far better long-term outcomes in both sexual function and co...
4D Brachytherapy is a hybrid approach to LDR brachytherapy for prostate cancer.
It combines the benefits of both a two-stage and one-stage implant technique to create a new real-time and dynamic approach to seed brachytherapy.
It not only eliminates some of the disadvantages aligned with each approach, but also introduces a host of added benefits.
Prostate brachytherapy is a targeted form of internal radiotherapy (sometimes referred to as low dose-rate or LDR brachytherapy). It is targeted only at the site of the tumour so the radiation kills the cancer cells without causing major damage to surrounding healthy cells. Tiny seeds containing the radiation are passed through fine needles and positioned directly into the prostate gland. It is not major surgery and usually patients will only spend 1 day in hospital. Most men return to their usual pre-treatment activities within a couple of days.
For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, according to research presented at the 58th Annual Meeting the American Society for Radiation Oncology (ASTRO).
Sydney siege survivor John O'Brien has returned home after life-prolonging surgery to stave off aggressive prostate cancer.
The former tennis pro and coach was rocked by the diagnosis, fearing he would no longer be around to care for his ill wife and daughter who suffers from severe bipolar disorder.